Dylan Fingerman

Dylan Fingerman

Auto-generated profile, based on publicly available information

Dylan Fingerman

Department of Pediatrics, Washington University School of Medicine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJae Ho Seo
Jae Ho Seo
YCYoung Chan Chae
Young Chan Chae
AKAndrew V. Kossenkov
Andrew V. Kossenkov
YLYu Geon Lee
Yu Geon Lee
HTHsin-Yao Tang
Hsin-Yao Tang
DADario C. Altieri
Dario C. Altieri
The regulators of mitochondrial cell death in cancer have remained elusive, hampering the development of new therapies. Here, we showed that protein isoforms of mitochondrial fission factor (MFF1 and MFF2), a molecule that controls mitochondrial size and shape, that is, mitochondrial dynamics, were overexpressed in patients with non–small cell lung cancer and formed homo- and heterodimeric complexes with the voltage-dependent anion channel-1 (VDAC1), a key regulator of mitochondrial outer membrane permeability. MFF inserted into the interior hole of the VDAC1 ring using Arg225, Arg236, and Gln241 as key contact sites. A cell-permeable MFF Ser223-Leu243 d-enantiomeric peptidomimetic disrupted the MFF–VDAC1 complex, acutely depolarized mitochondria, and triggered cell death in heterogeneous tumor types, including drug-resistant melanoma, but had no effect on normal cells. In preclinical models, treatment with the MFF peptidomimetic was well-tolerated and demonstrated anticancer activity in patient-derived xenografts, primary breast and lung adenocarcinoma 3D organoids, and glioblastoma neurospheres. These data identify the MFF–VDAC1 complex as a novel regulator of mitochondrial cell death and an actionable therapeutic target in cancer. Significance: These findings describe mitochondrial fission regulation using a peptidomimetic agent that disturbs the MFF–VDAC complex and displays anticancer activity in multiple tumor models. See related commentary by Rao, p. 6074

4 November 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
VJVaibhav Jain
Vaibhav Jain
SHSandra Harper
Sandra Harper
AVAmanda M. Versace
Amanda M. Versace
DFDylan Fingerman
Dylan Fingerman
GBGregory Schuyler Brown
Gregory Schuyler Brown
RARavi Amaravadi
Ravi Amaravadi
Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in multiple cancer cell lines. Lipidomics showed that LAI increased cholesterol, sphingolipids, and glycosphingolipids. These changes were associated with striking levels of GM1+ membrane microdomains (GMM) in plasma membranes and lysosomes. Inhibition of cholesterol/sphingolipid metabolism proteins enhanced LAI cytotoxicity. Targeting UDP-glucose ceramide glucosyltransferase (UGCG) synergistically augmented LAI cytotoxicity. Although UGCG inhibition decreased LAI-induced GMM and augmented cell death, UGCG overexpression led to LAI resistance. Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglustat combined with LAI significantly inhibited tumor growth and improved survival in syngeneic tumors and a therapy-resistant patient-derived xenograft. These findings nominate UGCG as a new cancer target, and clinical trials testing UGCG inhibition in combination with LAI are warranted. Significance: We discovered UGCG-dependent lipid remodeling drives resistance to LAI. Targeting UGCG with a drug approved for a lysosomal storage disorder enhanced LAI antitumor activity without toxicity. LAI and UGCG inhibition could be tested clinically in multiple cancers. This article is highlighted in the In This Issue feature, p. 247

9 December 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LLLorenz Loyola
Lorenz Loyola
VAVasudevan Achuthan
Vasudevan Achuthan
KGKathryn Gilroy
Kathryn Gilroy
GBGillian Borland
Gillian Borland
AKAnna Kilbey
Anna Kilbey
MRMonica Roth
Monica Roth
Murine leukemia virus (MLV) integrase (IN) lacking the C-terminal tail peptide (TP) loses its interaction with the host bromodomain and extraterminal (BET) proteins and displays decreased integration at promoter/enhancers and transcriptional start sites/CpG islands. MLV lacking the IN TP via an altered open reading frame was used to infect tumorigenesis mouse model (MYC/Runx2) animals to observe integration patterns and phenotypic effects, but viral passage resulted in the restoration of the IN TP through small deletions. Mice subsequently infected with an MLV IN lacking the TP coding sequence (TP-) showed an improved median survival by 15 days compared to wild type (WT) MLV infection. Recombination with polytropic endogenous retrovirus (ERV), Pmv20, was identified in seven mice displaying both fast and slow tumorigenesis, highlighting the strong selection within the mouse to maintain the full-length IN protein. Mapping the genomic locations of MLV in tumors from an infected mouse with no observed recombination with ERVs, TP-16, showed fewer integrations at TSS and CpG islands, compared to integrations observed in WT tumors. However, this mouse succumbed to the tumor in relatively rapid fashion (34 days). Analysis of the top copy number integrants in the TP-16 tumor revealed their proximity to known MLV common insertion site genes while maintaining the MLV IN TP- genotype. Furthermore, integration mapping in K562 cells revealed an insertion preference of MLV IN TP- within chromatin profile states associated with weakly transcribed heterochromatin with fewer integrations at histone marks associated with BET proteins (H3K4me1/2/3, and H3K27Ac). While MLV IN TP- showed a decreased overall rate of tumorigenesis compared to WT virus in the MYC/Runx2 model, MLV integration still occurred at regions associated with oncogenic driver genes independently from the influence of BET proteins, either stochastically or through trans-complementation by functional endogenous Gag-Pol protein. Many different retroviruses, including murine leukemia virus (MLV), are used as vectors for human gene therapy and cancer immunotherapies (CAR-T) because of their stable and efficient delivery of genetic material into the host DNA. However, this process can result in activation and/or disruption of cellular genes, which has resulted in the outgrowth of tumors in previous clinical trials. Of critical importance is the preferred location within the host genome at which the retrovirus integrates. Our study presents a modified MLV virus that has lost the ability to bind to the host BET proteins, the drivers of insertion at promoter/enhancer regions of highly activated genes. This is the first direct study within an animal model to examine whether infection with this type of modified MLV virus affects tumor progression. We found that the modified virus improved the survival of the well-characterized MYC/Runx2 mouse compared to infections with the wild-type MLV. Most modified viral integrants mapped into less active regions of the genome, but some integration events still occurred near cancer-related genes. Thus, while the modified MLV virus can be a safer vector than the wildtype virus, it still maintains the potential to activate oncogenes. This study provides new insights on how to improve the safety of MLV retroviral vectors.

31 March 2023
Verified
Other
Open access
JSJae Ho Seo
Jae Ho Seo
YCYoung Chan Chae
Young Chan Chae
AKAndrew V. Kossenkov
Andrew V. Kossenkov
YLYu Geon Lee
Yu Geon Lee
HTHsin-Yao Tang
Hsin-Yao Tang
DADario C. Altieri
Dario C. Altieri
Clinico-pathological characteristics of non-small cell lung cancer (NSCLC) patient series used in this study (n=72)

31 March 2023
Verified
Other
Open access
JSJae Ho Seo
Jae Ho Seo
YCYoung Chan Chae
Young Chan Chae
AKAndrew V. Kossenkov
Andrew V. Kossenkov
YLYu Geon Lee
Yu Geon Lee
HTHsin-Yao Tang
Hsin-Yao Tang
DADario C. Altieri
Dario C. Altieri
Requirements of MFF regulation of tumor cell death

31 March 2023
Verified
Other
Open access
JSJae Ho Seo
Jae Ho Seo
YCYoung Chan Chae
Young Chan Chae
AKAndrew V. Kossenkov
Andrew V. Kossenkov
YLYu Geon Lee
Yu Geon Lee
HTHsin-Yao Tang
Hsin-Yao Tang
DADario C. Altieri
Dario C. Altieri
Morphology of MFF targeting in tumor cells